JVDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Journal of Veterinary Diagnostic Investigation Vol. 20 Issue 1, 2-10
Copyright © 2008 by the American Association of Veterinary Laboratory Diagnosticians
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gavier-Widén, D.
Right arrow Articles by Baron, T. G.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gavier-Widén, D.
Right arrow Articles by Baron, T. G.M.

Full Scientific Reports

Bovine spongiform encephalopathy in Sweden: an H-type variant

Dolores Gavier-Widén1, Maria Nöremark, Jan P.M. Langeveld, Mick Stack, Anne-Gaëlle Biacabe, Johann Vulin, Melanie Chaplin, Jürgen A. Richt, Jorg Jacobs, Cristina Acín, Eva Monleón, Lena Renström, Berndt Klingeborn and Thierry G.M. Baron

Correspondence: 1Corresponding Author: Dolores Gavier-Widén, National Veterinary Institute, S-75189 Uppsala, Sweden. dolores{at}sva.se


   Abstract
TOP
 Sources and manufacturers
 Abstract
Introduction
 Material and Methods
 Results
 Discussion
 References
 
Bovine spongiform encephalopathy (BSE) had never been detected in Sweden until 2006, when the active surveillance identified a case in a 12-year-old cow. The case was an unusual form, because several molecular features of the protease-resistant prion protein (PrPres) were different from classical BSE. The differences included higher susceptibility for proteinase K, higher molecular weight of the PrPres bands, affinity to the N-terminus–specific antibodies 12B2 and P4, and peculiar banding pattern with antibody SAF84 showing an additional band at the 14 kDa position. The molecular characteristics were in accordance to previous descriptions of H-type BSE. This report shows that a range of Western blot techniques and antibodies can be applied to confirm H-type BSE and further describes that the ratio of the amounts of PrPres#1 and PrPres#2, after deglycosylation, depends on the antibody used during processing. Immunohistochemistry on sections of medulla at the level of the obex applying antibodies with epitopes covering a broad range of the PrP sequence showed accumulation of disease-specific PrP (PrPd) in the gray matter. Fine punctate deposition in the neuropil was the most predominant type and was more severe in BSE target nuclei. The types of PrPd deposition are described in comparison with classical BSE. PrP-gene sequencing showed 6 copy octarepeat alleles and no abnormalities. It is postulated that the disease had a spontaneous origin, rather than having had been acquired in the BSE epidemic.

Key Words: Atypical bovine spongiform encephalopathy • Nor98 • prion • scrapie • transmissible spongiform encephalopathy


   Introduction
TOP
 Sources and manufacturers
 Abstract
 Introduction
Material and Methods
 Results
 Discussion
 References
 
Transmissible spongiform encephalopathies (TSE) or prion diseases are infectious neurodegenerative diseases that are accompanied by accumulation of host-encoded prion protein (PrPc) in an aberrant or disease-associated prion protein (PrPSc or PrPd). Upon digestion with endoproteases, a partially resistant core known as PrPres remains.

Bovine spongiform encephalopathy (BSE) is a TSE primarily of cattle, but there is strong evidence that BSE has crossed the species barrier infecting humans and several species of animals.10,14,20,28,44 BSE was first identified in the United Kingdom in 1986,42 and its human form, variant Creutzfeldt-Jakob, was described in 1996.10,14 Bovine spongiform encephalopathy is transmitted by the dietary route and was spread in cattle by recycling of meat and bone meal. The resultant epidemic within the United Kingdom, most European countries, the United States, Japan, and Canada has been a major food safety concern and has had devastating effects in the beef industry.

Until recently, all cases of BSE from different geographical origins were thought to be caused by a single prion strain. This was based on 1) an invariable phenotype of disease in cattle,30,36,43 including consistent and homogenous patterns of immunostainings in the brain stem,12 2) a unique and consistent lesion profile, incubation time, and PrPd distribution in the brain of mouse models in biological strain typing of BSE from various sources, including human with variant Creutzfeldt-Jakob,7,9,18,29 and 3) similar biochemical features of the PrPres in natural and experimental BSE.37

However, bovine TSE that differs from classical BSE (C-type BSE) has been reported, mainly in older cattle. Initially, a case of BSE with an unusually low amount of diglycosylated banding and low-molecular-weight migration of the unglycosylated was reported in Japan in a 23-month-old Holstein steer.45 In Italy, 2 cows were reported to show PrPd deposition mostly as amyloid plaques, with different neuroanatomical distribution and aberrant molecular features, including an apparent predominance for the monoglycosylated form. The condition was named bovine amyloidotic spongiform encephalopathy.13 In France, 3 cases were also reported to have different molecular features than classical BSE. These cases were essentially characterized by a higher apparent molecular mass (Mr) of the unglycosylated form associated with binding by a PrP N-terminus–specific monoclonal antibody (MAb).6 The 2 unusual types of BSE were thereafter named L-type and H-type BSE, making reference to the lower and higher molecular weight of the unglycosylated band observed in the Italian and French cases, respectively.1,11 Additional cases of atypical BSE were reported in cattle1,11,21,32,34 and in a zebu (Bos indicus).35

Panels of antibodies against different regions of the prion protein can be used in Western blot (WB) and immunohistochemistry (IHC) to characterize the properties of PrPres and PrPd.5,24,41 Recently, it was shown that antibodies to PrP can be categorized into groups A, B, and C, which are thought to bind in the respective bovine PrP regions. Group A antibodies represent the 62–107 (N-terminal region), group B, the upstream amino acid sequence 109–164, and group C, 154–236 (C-terminal region).5 Using WB analysis of proteinase K (PK)–digested brain homogenates, all group A, B, and C antibodies yielded similar banding and glycoprofile patterns in C-type and L-type BSE. L-type was characterized by a similarity in relative concentrations of diglycosylated and monoglycosylated PrPres and C-type by a relative high concentration of diglycosylated PrPres.5,6,11,13,21 Group A antibodies 12B2 and P4 had a remarkable binding with H-type BSE but none or greatly reduced binding with C-type or L-type BSE. Of these 2 antibodies in group A, 12B2 is the most suitable for application in Bos genus because its epitope is fully present in bovine PrP and perhaps for discrimination of BSE strains in all animal species.21,27,33 Group B and C antibodies were reactive with all types of BSE, but these groups differed between each other when applied to H-type BSE in banding patterns and glycoprofiles.21 Group B antibodies to H-type BSE showed 1–2 kDa higher Mr of the PrPres fragments, and with group C antibodies a complex Western profile was shown in H-type BSE. This was characterized by the presence of 4 bands I to IV, respectively, including an additional unglycosylated band of 14 kDa. It was proposed that PrPres from H-type BSE was formed by a mixture of 2 triplet band populations, PrPres#1 and PrPres#2. PrPres#1 is reactive with group A, B, and C antibodies, while PrPres#2 is reactive only with group C antibodies. Each of these 2 populations is supposed to occur in diglycosylated, monoglycosylated, and unglycosylated forms.5

Bovine spongiform encephalopathy had never been detected in Sweden until the surveillance program in 2006 identified a case. The purpose of this report is to describe the clinical characteristics, to show the confirmatory WB results with a variety of techniques, and to show the results of further molecular investigation of the PrPres#1 and PrPres#2 using deglycosylation. This report also describes the first detailed study of the immunohistochemical PrPd deposition in an H-type case, in comparison to that found in C-type BSE.


   Material and Methods
TOP
 Sources and manufacturers
 Abstract
 Introduction
 Material and Methods
Results
 Discussion
 References
 
Animal, tissue sample
A 12-year-old mixed-breed Charolais cow, born on the farm, within a herd of 50 cows, located in Västmanland, central Sweden, was sent for rendering. A sample of brain stem was submitted to the National Veterinary Institute (SVA) of Sweden for TSE testing as part of the active BSE surveillance. The material was partially autolytic. The brain stem was cut sagitally in 2 hemisections; 1 part was fixed in 10% neutral buffered formalin, and another portion was used for rapid enzyme-linked immunosorbent assay (ELISA) screening test (Platelia/TeSeEa). The remaining unfixed tissue was used for WB and genotyping analysis according to methods previously described.34

Western blot analyses
For WB analysis the SVA utilized a commercial kit (Bio-Rad Bovine WBa). Samples of other prions diseases, C-type BSE, classical scrapie, and Nor98 were analyzed in parallel for comparison. Further WB analysis was performed at Veterinary Laboratories Agency (VLA; Weybridge, UK), Agence Francaise de Sécurité Sanitaire des Aliments (AFSSA; Lyon, France), and Central Institute for Animal Disease Control (Lelystad, The Netherlands). The antibodies used for the WB analyses, their source, and the sequence they recognize in the bovine PrP are shown in Table 1.


View this table:
[in this window]
[in a new window]

  		Table 1 Monoclonal antibodies employed in the Western blot and immunohistochemistry studies and the sequences recognized in the bovine prion protein.

 
The VLA applied 4 WB protocols: 1) the VLA hybrid discriminatory WB method, which discriminates between experimental BSE in sheep and natural sheep scrapie isolates using monoclonal antibodies (MAbs) 6H4 and P438,39; 2) the OIE-SAF WB using MAb 6H4 and ultracentrifugation37; 3) the Bio-Rad TeSeE WBa using MAb Sha 31; 4) the VLA sodium phosphotungstic acid WB using MAb 6H4 and P4, which is based on the incorporation of a sodium phosphotungstic acid–precipitation step to enhance the PrPres band signals.37 For comparison, a C-type BSE case from the UK was included in all of the analyses.

Methods employed for WB analysis at the AFSSA have been previously described in detail.5 The following MAbs and concentrations were applied: P4 (0.2 µg/ml), SHa31 (1:10), 12B2 (0.3 µg/ml), and SAF84 (0.150 µg/ml). Additional WB analysis after enzymatic deglycosylation by peptide:N-glycosidase F (PNGase) treatment was conducted as previously described.5 This analysis was used to study the relative proportions of PrPres#1 and PrPres#2 shown by the MAbs and their respective concentrations: F89/160.1.5 (200 ng/ml), 12F10 (100 ng/ml), SAF60 (ascitic fluid 1/5,000), SAF84 (150 ng/ml), 94B4 (35.5 ng/ml), and F99.97.6.1 (540 ng/ml). The labeling signals were quantified using VersaDoc 5000a digital capture and software Quantity One.a Methods used by Central Institute for Animal Disease Control for testing PK sensitivity of the case have been described in detail before.21

Histopathology and immunohistochemistry
Caudal brain stem was routinely processed, embedded in paraffin blocks, sectioned at 4 to 5 µm, and stained with hematoxylin and eosin and Congo red for visualization of amyloid. Blocks were not treated with formic acid. For IHC the sections were mounted on Vectabondc-treated glass slides, deparaffinized in xylene, and rehydrated. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Sections were incubated with normal horse serum (ABC Kitc) to block nonspecific binding sites. The sections were pretreated in 96% formic acid for 5 minutes followed by hydrated autoclaving in citrate buffer at 122°C for 30 minutes. Afterwards, they were incubated at room temperature for 60 minutes with 1 of the following primary MAbs and dilutions: F89/160.1 (1:1,900), F99/97.6.1 (1:2,000), P4 (1:1,000), 12F10 (1:400), 12B2 (0.2 µg/ml), 94B4 (2 µg/ml), and R145 (1 µg/ml). The amino acid sequences of the bovine PrP recognized by the MAbs and their source are shown in Table 1. The detection was conducted with the Vectastain ABC System,c and color was developed with aminoethylcarbazole substratec for all of the antibodies except for 12F10, which was developed with diaminobenzidine.c Sections were counterstained with hematoxylin. Each immunostain was accompanied by a positive reference control (obex of C-type BSE reference cases from Spain, 6 cases) and negative controls (obex of BSE negative cattle of matched age, 1 normal and 1 with listeriosis, and a primary antibody-omitted control of each section). Patterns of deposition of the PrPd and its intensity were assessed semiquantitatively in the reticular formation, dorsal motor nucleus of the vagus nerve (DMNV), nucleus of the solitary tract, cuneatus nuclei, nucleus of the spinal tract of the trigeminal nerve, and olivary nuclei.


   Results
TOP
 Sources and manufacturers
 Abstract
 Introduction
 Material and Methods
 Results
Discussion
 References
 
Clinical examination
The cow was in late pregnancy and showed sudden difficulties in rising. Clinical examination revealed lateral recumbency and tympany, and the rectal temperature was 37.0°C. Reactions to pain stimuli and muscle tone in both hind limbs were normal. There were no signs of fractures of the pelvis, and the calf and uterus were in normal position. General appearance was normal, and there were no signs of nervousness or abnormal behavioral reactions. The cow was treated with calcium and a nonsteroidal anti-inflammatory drug and was standing a few hours later. The next morning she was again in recumbence. A blood sample was obtained, the same treatment administered, and she was walking 30 minutes later. The veterinarian noted a slight lameness on the left hind limb but no ataxia. Serum calcium was normal, but there was increased creatinine kinase. On the third day, the cow was recumbent again, and she was treated with prostaglandins to initiate parturition. Three days later, when parturition did not occur, she was culled.

Rapid test
The ELISA screening test was positive in the first run, with an optical density (OD) value of 2.42, in a second run in 2 wells (OD values 2.77 and 2.88), and in a subsequent testing of a second homogenate (OD value of 3.22). The cutoff value was 0.22 in all of the runs.

Western blot
All of the WB analyses detected PrPres and therefore confirmed the case as a TSE. The WB test at the SVA using MAb Sha31 showed a higher molecular weight of the unglycosylated band (and the 2 glycosylated bands) than in the C-type BSE control (Fig. 1A). Compared with scrapie samples, the Swedish case also exhibited a higher molecular weight of the bands than classical scrapie and a different banding pattern than Nor98 atypical scrapie.


Figure 01
View larger version (41K):
[in this window]
[in a new window]

  		Figure 1 Western blot (WB) analyses of the Swedish H-type BSE case conducted on the brain stem. The bars indicate the position of molecular markers (kDa). A, WB analysisa with antibody SHa31 conducted at the SVA. Note the higher position of the lower (unglycosylated) band in the Swedish H-type BSE than in the classical BSE (C-type) control. Compared with scrapie samples, the Swedish case also exhibited a higher molecular weight of the bands than classical scrapie and a different banding pattern than Nor98 atypical scrapie. B, WB analysis with antibody SAF84 conducted at the AFSSA. Note the similar banding pattern in the Swedish and French H-type cases with 4 bands at positions 27, 23, 18, and 14 kDa (bands I to IV), the large proportion of band II and wide band III. The arrow points at the thin and dark upper part of band III, at approximately 19 kDa.

 
Results of the various WB methods revealed the following molecular characteristics, which discriminate the Swedish case from C-BSE: higher molecular weight of the unglycosylated band than in the C-type BSE when using the group B antibodies, such as SHa31 (Fig. 1A), labeling with group A MAb P4 and 12B2, particularly strong with the latter, enhanced sensitivity for PK digestion, and a 4-banding pattern with a group C antibody (Fig. 1B). In addition to these previously described features of H-type BSE, the proportion of PrPres#1 to PrPres#2 in enzymatically deglycosylated samples was very different depending of the group C antibody used (Fig. 2). The ratio PrPres#1/PrPres#2 was 80/20 with SAF84 and F99/160.1.5, 56/44 with SAF60, and 39/61 with 94B4.


Figure 02
View larger version (62K):
[in this window]
[in a new window]

  		Figure 2 Western blot (WB) analysis of PrPres with antibodies F99/97.6.1 (1) or 94B4 (2) after PNGase F treatment. 1A and 2A: first and second lane: classical BSE from France and The Netherlands; third to sixth lanes H-type BSE cases: 2 French, 1 Dutch, and the Swedish case, respectively. In H-type BSE PrPres#1 run at about 20 kDa and PrPres#2 at about 14 kDa. 1B and 2B: relative proportion of PrPres#1 (dark bar) and PrPres#2 (light bar) detected by WB (mean and standard deviation of 4 cases) with F99/97.6.1 (1b) or 94B4 (2b).

 
Histopathology and immunohistochemistry
Samples from this case for histopathology and IHC were of poor quality; however, a few vacuoles in the neuropil in the solitary tract nucleus and the nucleus of the spinal tract of the trigeminal nerve resembled lesions described with BSE (Fig. 3A). No amyloid was observed. All the antibodies applied in IHC resulted in immunostaining, but the intensity of different PrPd types varied with the different antibodies. The average score for the neuroanatomical areas for each type of PrPd in the Swedish H-type case and in the C-BSE cases is shown in Table 2. The most frequent PrPd type in the Swedish case was thin punctate deposition in the neuropil (Fig. 3A, 3B), which sometimes coalesced into coarser granules (Fig. 3B). Staining was diffuse in the gray matter and was strongest with F89.160.1. Neuropil PrPd deposition was more intense, with all of the MAbs, in the lateral aspects of the nucleus of the spinal tract of the trigeminal nerve (Fig. 3C) followed by the solitary tract nucleus. Perineuronal (Fig. 3F) and to a lesser extent linear (Fig. 3E) depositions were also observed. The MAbs F99.97.6.1 and R145 produced the most concentrated intracellular PrPd deposits (Fig. 3E, 3G). Antibodies 94B4 showed it only in a few neurons, mostly in the reticular formation, while MAbs P4, 12B2, 12F10, and F89.160.1 did not show either intraneuronal or intramicroglial accumulations. In general, the accumulation of intraneuronal granules of PrPd were more evident in the large neurons of the cuneatus and olivary nuclei and of the reticular formation. Within the reticular formation, there was a high degree of variation in the intensity of intraneuronal PrPd deposition and in the number of neurons affected. No other PrPd types could be identified. In C-type BSE, the MAbs 12B2 and P4 produced extracellular immunostaining, but only in the cases with heaviest PrPd deposition. Antibodies 12F10 and F89.160.1 showed abundant intracellular PrPd accumulation.


Figure 03
View larger version (169K):
[in this window]
[in a new window]

  		Figure 3 Immunohistochemistry of sections of medulla at the level of the obex of the Swedish atypical H-type BSE case. A, solitary tract nucleus (star) with PrPd deposition (brown) in the neuropil. Antibody F89.160.1. A few neuropil vacuoles can be identified (arrowheads). B, higher magnification of nucleus of the solitary tract illustrates the most predominant type of PrPd: thin punctate accumulation. A coarse aggregate of PrPd is also shown (arrowhead). Antibody F89.160.1. C, intense PrPd extracellular deposition (dark brown or black) in lateral aspects (branches) of the nucleus of the spinal tract of the trigeminal nerve. The white fibers of the trigeminal tract remain unstained (gray). Antibody 12F10. D, intramicroglial PrPd is shown in the reticular formation mostly as single large granules (arrowheads) next to nuclei of apparently microglial cells. Antibody F99.97.6.1. E, extracellular PrPd deposition, granular and linear immunolabeling (narrow arrowhead), and intracellular PrPd accumulation; intramicroglial (arrow) and intraneuronal (broad arrowhead) are shown in the reticular formation with antibody F99.97.6.1. F, extracellular perineuronal PrPd deposition as granules along the perikarya. Reticular formation. Antibody P4. G, intraneuronal granular accumulation of PrPd in nucleus cuneatus revealed by a C-terminal antibody, R145. Bar = 50 µm.

 

View this table:
[in this window]
[in a new window]

  		Table 2 Summary of the intensity* of PrPd deposition types produced by several PrP antibodies in the brain stem of C-type BSE and a case of H-type BSE in Sweden.

 
Sequencing of the prion protein gene
The prion protein alleles of the cow were found to be normal (i.e., having unremarkable cattle-like PrP gene sequences). The animal had synonymous polymorphisms at codon 23 (L23L, CTC/CTT) and codon 78 (Q78Q, CAG/CAA), and both alleles contained the 6-copy octapeptide repeat region.


   Discussion
TOP
 Sources and manufacturers
 Abstract
 Introduction
 Material and Methods
 Results
 Discussion
References
 
Results reported here indicated that the Swedish cow was affected by a TSE different from epizootic classical (C-type) BSE. Several differences in biochemical features of PrPres included: the position of the PrPres fragments, with a higher molecular weight of the monoglycosylated and the unglycosylated PrPres bands, the antibody affinity, with binding to group A, N-terminus–specific antibodies, the markedly higher susceptibility for PK under stringent conditions of pH and PK concentration, and the peculiar 4-band pattern (bands I to IV) with group C antibody, including an additional band (band IV) at about the 14 kDa position. In addition, the occurrence of 2 bands after enzymatic deglycosylation of PrPres with PNGase F was different from the C-type. The Swedish case closely resembles descriptions for H-type BSE in Europe5,6,11,21 and the United States.34 This report indicates that H-type BSE can be diagnosed and/or confirmed by several different WB methods.

In the present study, the complexity of WB features with C-terminal antibodies was in agreement to a previous description of H-type BSE.5 The 4-band pattern can be best explained by the existence of 2 PrPres triplet-band populations (PrPres#1 and PrPres#2) reactive with antibodies specific for region 154-242 of bovine PrP. The WB investigations showed additionally that the apparent proportion of the 2 PrPres populations was dependant on the C-terminal antibodies used. With group C antibodies, the different PrPres#1/PrPres#2 ratios as shown after enzymatic deglycosylation (Fig. 2) can be attributable to differences in affinities between antibodies and epitope structure and cleavage by PK between the PrPres populations.

Histopathologic examination was hampered by autolysis and was only possible in the medulla region. Nonetheless, a few neuropil vacuoles typical for BSE were identified in BSE-target nuclei. The PrPd deposits observed by IHC confirmed the case as a prion disease. In well-preserved tissues, IHC allows a detailed evaluation of the cellular location and morphological characteristics of the PrPd accumulation.17 In scrapie, particular patterns of intracellular and extracellular PrPd deposition have been described using IHC and electron microscopy.22,23 Similar patterns were recognized in this study. Immunohistochemistry using a range of antibodies that bind different peptide regions of the prion protein shows differences in the recognition of intracellular PrPd accumulations between scrapie and BSE.17 Differences between BSE and scrapie are attributed to variations in intracellular truncation at the N-terminus of PrPd, and are probably a result of differences in the conformation of the molecule.17,40 In the present study, some information was obtained as to the epitope recognition of the PrPd in the Swedish H-type case by the various antibodies tested. A full description of cellular localization and of the PrPd distribution in the brain could not be performed because of the insufficient quality and quantity of the material. Little information is available about the PrPd deposition in C-BSE with a range of antibodies; therefore, for comparison purposes, this study included a description of the reference C-BSE control cases.

In general, the distribution and morphology of the immunostaining for most antibodies was similar in C-type BSE and the H-type. In both, the MAbs directed to epitopes located C-terminally, F99.97.6.1 and R145 showed marked intracellular (intraneuronal and intramicroglial) PrPd deposition, while antibodies directed to more N-terminal–located epitopes, such as P4 and 12B2, did not reveal this type of staining. Nonetheless, some differences were observed in the immunostaining types and/or intensity between the C-type BSE reference sections and the H-type case. Perhaps differences were a result of the poor preservation and loss of tissue structure in the Swedish case. For example, in the H-type case stellate PrPd accumulation could not be identified, and there were antibody-dependent variations with respect to intraneuronal PrPd deposition. In C-type BSE sections, intraneuronal and intramicroglial accumulation was shown with core specific antibodies F89.160.1 and 12F10, but this was not evident in the atypical case. It is possible that the lack of demonstration of intracellular PrPd with these 2 antibodies in the Swedish case may reflect a truncation at a more upstream level than in C-type BSE. On the other hand, intracellular labeling with MAb 12F10 has been reported in an H-type BSE case in Germany.11 Also intraneuronal PrPd with MAb P4 was reported in an H-type case in a zebu.35 These different results may be attributed to the use of different protocols or the tissue quality. Alternatively, it is possible that different subtypes of H-type BSE exist, with possible variations in their immunohistochemical features. The cow in this report had signs that yielded no definitive clinical diagnosis, but symptoms of C-type BSE can vary, and other conditions may mask BSE.25

Little information is available about clinical signs associated to H-type BSE. In this report it was not clear if the clinical signs in the cow were related to the TSE or hypocalcemia.

Experimental intracerebral inoculation of French and German H-type BSE in 2 different bovine transgenic mouse lines (TgXV and tg540) produced neurological disease in all of the mice following incubation periods as well as PrPres molecular features and brain lesions that were distinctly different from C-type BSE. These results suggest atypical H-type cases harbor a prion strain different from classical BSE.4,11 Other transmission studies, in wild-type C57B/6 mice, classically used for strain typing of BSE, also indicated the isolation of a different strain,2 and especially showed that the distinct PrPres molecular features, which are similar to those described in this report,5 were maintained after transmission in mice. Transmission studies of the Swedish case into transgenic mice are currently in progress.

The origin of C-type BSE remains enigmatic, and the discovery of the atypical types of BSE has given rise to further hypotheses.1,6,8,13,21 It has been proposed that unusual forms of BSE arise as a sporadic disease in cattle, perhaps related to old age, and comparable to sporadic Creutzfeldt-Jakob disease, or possibly to the Nor98 variant of scrapie in sheep and goats.3 It can also be hypothesized that sporadic BSE has occurred in the past and that it initiated the BSE epidemic by contamination of feed. It should be noted, however, that this would have resulted in a change of the molecular and biological properties of the agent, from H-type to C-type. Genetic studies in the Swedish case do not support the possibility of H-type BSE being caused by a germ-line mutation in the prion gene. This supports previous reports in 3 French H-type cases.6 To date no cases of C-type BSE have been detected in Sweden. The TSE Swedish case showed similarities with previous descriptions of H-type BSE cases. The screening methods for BSE surveillance in Sweden were able to identify an H-type BSE case. Uncertainties remain concerning the origin and potential infectivity of atypical BSE cases for humans and animals.


   Acknowledgments
 
The authors acknowledge the support of NeuroPrion. They especially thank M. Simmons for the confirmation of the BSE case at the Community Reference Laboratory, VLA, Weybridge, R. Feinstein and M. Elvander, SVA, for their contribution to the initial diagnosis, and E. Westergren and L. Ottander for their technical help with the immunohistochemistry. The authors are grateful to B. Ekberg for his technical help with the illustrations, Linda Terry, VLA, for supplying the MAbs R145, and Sylvie Benestad for her helpful review of the manuscript. Thanks to S. Wallgren and A. Odhelius for providing detailed information on the clinical signs and for their examinations of the cow. The Dutch Ministry of Agriculture, Nature, and Food Quality financially supported this work (project 8041889000) as well as the NeuroPrion task group Eurostrain (EC FOOD-CT-2004-506579).


   Sources and manufacturers
TOP
 Sources and manufacturers
Abstract
 Introduction
 Material and Methods
 Results
 Discussion
 References
 
From the National Veterinary Institute, Uppsala, Sweden (Gavier-Widén, Nöremark, Renström, Klingeborn), the Agence Francaise de Sécurité Sanitaire des Aliments, Lyon Cedex 07, France (Biacabe, Vulin, Baron), the Central Institute for Animal Disease Control, Wageningen UR, Lelystad, The Netherlands (Langeveld, Jacobs), the Veterinary Laboratory Agency, Weybridge, New Haw, Addlestone, Surrey, UK (Stack, Chaplin), the National Animal Disease Center, Ames, IA (Richt), and the University of Zaragoza, Zaragoza, Spain (Acín, Monleón). Back

a Bio-Rad, Marnes, la Coquette, Paris, France. Back

b Prionics AG, Schlieren, Switzerland. Back

c Vector Laboratories, Inc., Burlingame, CA. Back

d Available at Central Institute for Animal Disease Control, Lelystad, The Netherlands. Back

e BioPharm Ltd., Darmstadt, Germany. Back

f VMRD Inc., Pullman WA. Back

g Cayman Chemical, Ann Arbor, MI. Back

h Jacques Grassi, CEA, Saclay, Gif sur Yvette, France. Back

i SPI-BIO, Montigny le Bretonneux, France. Back

j Kindly supplied by Dr. Linda Terry, Veterinary Laboratory Agency, UK. Back


   References
TOP
 Sources and manufacturers
 Abstract
 Introduction
 Material and Methods
 Results
 Discussion
 References
 

  1. Baron T., Biacabe A.G., Arsac J.N., et al.: 2007, Atypical transmissible spongiform encephalopathies (TSEs) in ruminants. Vaccine 25:5625–5630.[Medline]
  2. Baron T.G.M., Biacabe A.G., Bencsik A., Langeveld J.P.M.: 2006, Transmission of new bovine prion to mice. Emerg Infect Dis 12:1125–1128.[Medline]
  3. Benestad S.L., Sarradin P., Thu B., et al.: 2003, Cases of scrapie with unusual features in Norway and designation of a new type, Nor98. Vet Rec 153:202–208.[Abstract/Free Full Text]
  4. Beringue V., Bencsik A., Le Dur A., et al.: 2006, Isolation from cattle of a prion strain distinct from that causing bovine spongiform encephalopathy. PLOS Pathogens 10:956–963.
  5. Biacabe A.G., Jacobs J.G., Bencsik A., et al.: 2007, H-type bovine spongiform encephalopathy. Complex molecular features and similarities with human prion diseases. Prion 1:61–68.
  6. Biacabe A.G., Laplanche J.L., Ryder S., Baron T.: 2004, Distinct molecular phenotypes in bovine prion diseases. EMBO Rep 5:110–115.[Medline]
  7. Brown D.A., Bruce M., Fraser J.R.: 2003, Comparison of the neuropathological characteristics of bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob (vCJD) in mice. Neuropathol Appl Neurobiol 29:262–272.[Medline]
  8. Brown P., McShane L.M., Zanusso G., Detwiler L.: 2006, On the question of sporadic or atypical bovine spongiform encephalopathy and Creutzfeldt-Jakob disease. Emerg Infect Dis 12:1816–1821.[Medline]
  9. Bruce M., Chree A., McConnell I., et al.: 1994, Transmission of bovine spongiform encephalopathy and scrapie to mice: strain variation and the species barrier. Phil Trans R Soc Lond B Sci 343:405–411.
  10. Bruce M.E., Will R.G., Ironside J.W., et al.: 1997, Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 389:498–501.[Medline]
  11. Buschmann A., Gretzschel A., Biacabe A.G., et al.: 2006, Atypical BSE in Germany—proof of transmissibility and biochemical characterization. Vet Microbiol 117:103–116.[Medline]
  12. Casalone C., Caramelli M., Crescio M.I., et al.: 2006, BSE immunohistochemical patterns in the brainstem: a comparison between UK and Italian cases. Acta Neuropathol (Berl) 111:444–449.[Medline]
  13. Casalone C., Zanusso G., Acutis P., et al.: 2004, Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA 101:3065–3070.[Abstract/Free Full Text]
  14. Collinge J., Sidle K., Meads J., et al.: 1996, Molecular analysis of prion strain variation and the etiology of "new variant" CJD. Nature 383:685–690.[Medline]
  15. Demart S., Fournier J.G., Creminon C., et al.: 1999, New insight into abnormal prion protein using monoclonal antibodies. Biochem Biophys Res Commun 265:652–657.[Medline]
  16. Feraudet C., Morel N., Simon S., et al.: 2005, Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells. J Biol Chem 280:11247–11258.[Abstract/Free Full Text]
  17. Gonzalez L., Martin S., Jeffrey M.: 2003, Distinct profiles of PrPd immunoreactivity in the brain of scrapie and BSE-infected sheep: implications for different cell targeting and PrP processing. J Gen Virol 84:1339–1350.[Abstract/Free Full Text]
  18. Green R., Horrocks C., Wilkinson A., et al.: 2005, Primary isolation of the bovine spongiform encephalopathy agent in mice: agent definition based on a review of 150 transmissions. J Comp Path 132:117–131.[Medline]
  19. Harmeyer S., Pfaff E., Groschup M.H.: 1998, Synthetic peptide vaccines yield monoclonal antibodies to cellular and pathological prion proteins of ruminants. J Gen Virol 79:937–945.[Abstract]
  20. Hill A., Desbruslais F., Joiner M., et al.: 1997, The same prion strain causes vCJD and BSE. Nature 389:448–450.[Medline]
  21. Jacobs J.G., Langeveld J.P.M., Biacabe A.G., et al.: 2007, Molecular discrimination of atypical bovine spongiform encephalopathies from a wide geographical region in Europe. J Clin Microbiol 45:1821–1829.[Abstract/Free Full Text]
  22. Jeffrey M., Wells G.A.H., Bridges A.W.: 1990, An immunohistochemical study of the topography and cellular localization of three neural proteins in the sheep nervous system. J Comp Pathol 103:23–35.[Medline]
  23. Jeffrey M., Goodsir C.M., Bruce M.E., et al.: 1994, Murine scrapie-infected neurons in vivo release excess prion protein into the extracellular space. Neurosci Lett 174:39–42.[Medline]
  24. Jeffrey M., González L., Chong A., et al.: 2006, Ovine infection with the agents of scrapie (CH1641 isolate) and bovine spongiform encephalopathy: immunochemical similarities can be resolved by immunohistochemistry. J Comp Pathol 134:17–29.[Medline]
  25. Konold T., Sivam S.K., Ryan J., et al.: 2006, Analysis of clinical signs associated with bovine spongiform encephalopathy in casualty slaughter cattle. Vet J 171:438–444.[Medline]
  26. Korth C., Stierli B., Streit P et a.l.: 1997, Prion (PrPSc)–specific epitope defined by a monoclonal antibody. Nature 390:74–77.[Medline]
  27. Langeveld J.P.M., Jacobs J.G., Erkens J.H.F., et al.: 2006, Rapid and discriminatory diagnosis of scrapie and BSE in retro-pharyngeal lymph nodes of sheep. BMC Vet Res [serial online]. 2:19. Available from: BioMed Central Ltd. London, UK. Accessed Oct. 31, 2007.
  28. Lasmézas C.I., Deslys J-P., Demalmay R., et al.: 1996, BSE transmission to macaques. Nature 381:743–744.[Medline]
  29. Lezmi S., Bencsik A., Baron T.: 2006, PET-blot analysis contributes to BSE strain recognition in C57BI/6 mice. J Histochem Cytochem 54:1087–1094.[Abstract/Free Full Text]
  30. Orge L., Simas J.P., Fernades A.C., et al.: 2000, Similarity of the lesion profile of BSE in Portuguese cattle to that described in British cattle. Vet Rec 147:486–488.[Free Full Text]
  31. O'Rourke K.I., Bazler T.V., Besser T.E., et al.: 2000, Preclinical diagnosis of scrapie by immunohistochemistry of third eyelid lymphoid tissue. J Clin Microbiol 38:3254–3259.[Abstract/Free Full Text]
  32. Polak M.P., Rozek W., Rola J., Zmudzinski J.F.: 2004, Prion protein glycoforms from BSE cases in Poland. Bull Vet Inst Pulawy 204:201–205.
  33. Polak M.P., Zmudzinski J.F., Jacobs J.G., Langevled J.P.M.: 2007, Atypical status of bovine spongiform encephalopathy in Poland: a molecular typing study. Arch Virol. Epub 2007 Sep 26.
  34. Richt J.A., Kunkle R.A., Alt D., et al.: 2007, Identification and characterization of two bovine spongiform encephalopathy cases diagnosed in the United States. J Vet Diagn Invest 19:142–154.[Abstract/Free Full Text]
  35. Seuberlich T., Botteron C., Wenker C., et al.: 2006, Spongiform encephalopathy in a miniature zebu. Emerg Infect Dis 12:1950–1953.[Medline]
  36. Simmons M.M., Harris P., Jeffrey M et a.l.: 1996, BSE in Great Britain: consistency of the neurohistopathological findings in two random annual samples of clinically suspect cases. Vet Rec 138:175–177.[Abstract/Free Full Text]
  37. Stack M.: 2004, Western immunoblotting techniques for the study of transmissible spongiform encephalopathies. In: Methods and tools in biosciences and medicine—techniques in prion research, Lehmann S., Grassi J., pp. 97–116. Birkhäuser Verlag, Berlin, Germany.
  38. Stack M.J., Chaplin M.J., Clark J.: 2002, Differentiation of prion protein glycoforms from naturally occurring sheep scrapie, sheep passaged scrapie strains (CH1641 and SSBP1), bovine spongiform encephalopathy (BSE) cases and Romney and Cheviot breed sheep experimentally inoculated with BSE using two monoclonal antibodies. Acta Neuropathol 104:279–286.[Medline]
  39. Stack M., Jeffrey M., Gubbins S., et al.: 2006, Monitoring for BSE in sheep in Great Britain 1998-2004. J Gen Virol 87:2099–2107.[Abstract/Free Full Text]
  40. Thuring C.M., Erkens J.H., Jacobs J.G., et al.: 2004, Discrimination between scrapie and bovine spongiform encephalopathy in sheep by molecular size, immunoreactivity, and glycoprofile of prion protein. J Clin Microbiol 42:972–980.[Abstract/Free Full Text]
  41. Thuring C.M.A., Van Keulen L.J.M., Langeveld J.P.M., et al.: 2005, Immunohistochemical distinction between preclinical bovine spongiform encephalopathy and scrapie infection in sheep. J Comp Pathol 132:59–69.[Medline]
  42. Wells G.A., Scott A.C., Johnson C.T., et al.: 1987, A novel progressive spongiform encephalopathy in cattle. Vet Rec 121:419–420.[Medline]
  43. Wells G.A.H., Simmons M.M.: 1996, The essential lesion profile of bovine spongiform encephalopathy (BSE) in cattle is unaffected by breed or route of infection. Neuropathol Appl Neurobiol 22:453. pp.
  44. Will R.G., Ironside J.W., Zeidler M., et al.: 1996, A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347:921–925.[Medline]
  45. Yamakawa Y., Hagiwara K., Nohtomi K., et al.: 2003, Atypical proteinase K-resistant prion protein (PrPres) observed in an apparently healthy 23-month-old Holstein steer. Jpn J Infect Dis 56:221–222.[Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gavier-Widén, D.
Right arrow Articles by Baron, T. G.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gavier-Widén, D.
Right arrow Articles by Baron, T. G.M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS